Octreotide induced remission of a refractory small cell carcinoma of the endometrium

International Journal of Gynecological Cancer

Volumn 9, Issue 1, 1999, Pages 80-85

  Verschraegen, C F ^a   Matei, C ^a   Loyer, E ^a   Malpica, A ^a   Tornos, C ^b   Kudelka, A P ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Neuroendocrine markers; Octreotide; Small cell carcinoma; Somatostatin; Uterus

Indexed keywords

CISPLATIN; ETOPOSIDE; LEUPRORELIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; TAMOXIFEN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARGYROPHILIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG EFFECT; ENDOMETRIUM CARCINOMA; FEMALE; GROWTH INHIBITION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SMALL CELL CARCINOMA; TUMOR GROWTH;

EID: 0033048495     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.09886.x     Document Type: Article

References (29)

1. Ueda G, Yamasaki M. Neuroendocrine carcinoma of the uterus. Curr Top Pathol 1992; 85: 319-35.
2. Abeler V, Kjorstad K, Nesland J. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer 1991; 68: 98-105.
3. van Hoeven KH, Hudock J, Woodruff J, Suhrland M. Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol 1995; 14: 21-9.
4. Huntsman D, Clement P, Blake Gilks C, Scully R. Small cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol 1994; 18: 364-75.
5. Campo E, Brunier M, Merino M. Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. Cancer 1992; 69: 2283-8.
6. Savargaonkar PR, Hale RJ, Mutton A, Manning V, Buckley CH. Neuroendocrine differentiation in cervical carcinoma. J Clin Pathol 1996; 49: 139-41.
7. Moore T, Phillips P, Nerenstone S, Cheson B. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 1991; 9: 1071-88.
8. Lamberts S, van der Lely A, de Herder W, Hofland L. Octreotide. N Engl J Med 1996; 336: 246-54.
9. Saltz L, Trochanowski B, Buckley M et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993; 72: 244-8.
10. Chaudhry A, Kvols L. Advances in the use of somatostatins in the management of endocrine tumors. Curr Opin Oncol 1996; 8: 44-8.
11. Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 1992; 65: 505-18.
12. Lamberts S, Reubi JC, Krenning E. The role of somatostatin analogs in the control of tumor growth. Semin Oncol 1994; 13: 61-4.
13. Mosdell K, Visconti J. Emerging indications for octreotide therapy. Part 1. Am J Hosp Pharm 1994; 51: 1184-92.
14. Schally A. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977-85.
15. Anthony L, Johnson D, Hande K et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993; 32: 217-23.
16. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997; 70: 530-7.
17. Moertel C, Kvols L, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
18. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant C. The somatostatin receptor family. Life Sci 1995; 57: 1249-65.
19. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocrinol Rev 1995; 16: 427-42.
20. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994; 54: 3455-9.
21. Cotto C, Quoix E, Thomas F, Henane S, Trillet-Lenoir V. Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma. Ann Oncol 1994; 5: 290-1.
22. Hagiwara K, Kobayashi T, Tobita M, Kikyo N, Yazaki Y, Okabe T. Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer cells: its identity with insulin-like growth factor II. Jpn J Cancer Res 1995; 86: 202-7.
23. Piaditis GP, Hatziioanidis AH, Trovas GP et al. The effect of sequential administration of octreotide alone and octreotide growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome. Clin Endocrinol 1996; 45: 595-604.
24. Bartolomeo M, Bajetta E, Buzzoni R et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77: 402-8.
25. Arnold R, Trautmann ME, Creutzfeld W et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996; 38: 430-8.
26. Goldberg R, Moertel C, Winand H et al. A phase III evaluation of a somatostatin analogue (Octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 1995; 76: 961-6.
27. Cascinu S, Del Ferro E, Grianti C et al. Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterol 1997; 113: 767-72.
28. Pollak MN, Ingle JN, Suman VJ, Kugler JW, Nickerson T, Deroo B. Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast cancer patients by coadministration of the somatostatin analog octreotide. Proc Am Assoc Cancer Res 1996; 37: A1167.
29. Vainas G, Pasaitou V, Galaktidou G et al. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. J Exp Clin Cancer Res 1997; 16: 119-26.